This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheung, C. C. Articles by Asa, S. L. Search for Related Content PubMed PubMed Citation Articles by Cheung, C. C. Articles by Asa, S. L.

Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma¹

Departments of Pathology and Laboratory Medicine, Medicine (Endocrinology), and Otolaryngology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1X5

Address all correspondence and requests for reprints to: Dr. Sylvia L. Asa, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: sasa{at}mtsinai.on.ca

Among thyroid neoplasms, Hurthle cell tumors (HCTs) have traditionally been a distinct diagnostic category. Hurthle cell adenomas are encapsulated follicular lesions with benign behavior. Hurthle cell carcinomas exhibit unequivocal capsular and/or vascular invasion; they are aggressive tumors with a poor prognosis. Recently, Hurthle cell papillary thyroid carcinomas (PTCs) have been identified on morphological grounds. We hypothesize that a subset of HCTs represent PTC with clinical, histological, and immunohistochemical features based on specific molecular events. ret/PTC gene rearrangements give rise to novel oncogenes that are unique to PTC. We studied a group (n = 50) of HCTs for ret/PTC gene rearrangements. Tumors were examined for papillary differentiation by light microscopic evaluation of nuclear features, by RT-PCR for ret/PTC gene rearrangements, and by immunohistochemistry for ret. Among 24 noninvasive tumors, 13 contained ribonucleic acid for ret/PTC-1, -2, or –3, and 9 of these were immunoreactive for ret. Among 19 Hurthle cell carcinomas, 15 had focal nuclear hypochromasia with grooves and/or inclusions; expressed transcripts of ret/PTC-1, -2, or –3; and exhibited ret positivity. Tumors with ret/PTC gene rearrangements tended to have lymph node metastases rather than hematogenous spread. Our results indicate that a subset of HCTs exhibit features of PTC that are attributable to specific gene rearrangements, resulting in expression of ret/PTC oncogenes. These data support subclassification of HCTs into three groups: Hurthle cell adenomas, Hurthle cell carcinomas, and Hurthle cell PTC.

This article has been cited by other articles:

				R. Flavin, G. Jackl, S. Finn, P. Smyth, M. Ring, E. O'Regan, S. Cahill, K. Unger, K. Denning, Jinghuan Li, et al. RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma International Journal of Surgical Pathology, June 1, 2009; 17(3): 187 - 197. [Abstract] [PDF]

				M. Santoro, R. M. Melillo, and A. Fusco RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653. [Abstract] [Full Text] [PDF]

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				K. J. Rhoden, K. Unger, G. Salvatore, Y. Yilmaz, V. Vovk, G. Chiappetta, M. B. Qumsiyeh, J. L. Rothstein, A. Fusco, M. Santoro, et al. RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimoto's Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2414 - 2423. [Abstract] [Full Text] [PDF]

				E. L. Maxwell, C. E. Palme, and J. Freeman Hurthle Cell Tumors: Applying Molecular Markers to Define a New Management Algorithm Arch Otolaryngol Head Neck Surg, January 1, 2006; 132(1): 54 - 58. [Abstract] [Full Text] [PDF]

				M. Sobrinho-Simoes, V. Maximo, I. V. de Castro, E. Fonseca, P. Soares, G. Garcia-Rostan, and M. C. de Oliveira Hurthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance International Journal of Surgical Pathology, January 1, 2005; 13(1): 29 - 35. [Abstract] [PDF]

				K. T. Mai, G. Elmontaser, D. G. Perkins, J. Thomas, and W. A. Stinson Benign Hurthle Cell Adenoma with Papillary Architecture: A Benign Lesion Mimicking Oncocytic Papillary Carcinoma International Journal of Surgical Pathology, January 1, 2005; 13(1): 37 - 41. [Abstract] [PDF]

				S. Sadetzki, R. Calderon-Margalit, B. Modan, S. Srivastava, and R. M. Tuttle Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2281 - 2289. [Abstract] [Full Text] [PDF]

				S L Asa My approach to oncocytic tumours of the thyroid J. Clin. Pathol., March 1, 2004; 57(3): 225 - 232. [Abstract] [Full Text] [PDF]

				C. A. French, E. K. Alexander, E. S. Cibas, V. Nose, J. Laguette, W. Faquin, J. Garber, F. Moore Jr, J. A. Fletcher, P. R. Larsen, et al. Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer Am. J. Pathol., April 1, 2003; 162(4): 1053 - 1060. [Abstract] [Full Text] [PDF]

				J. A. Fagin Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-Specific Therapeutic Targets Endocrinology, June 1, 2002; 143(6): 2025 - 2028. [Full Text] [PDF]

				T. G. Kroll Molecular Rearrangements and Morphology in Thyroid Cancer Am. J. Pathol., June 1, 2002; 160(6): 1941 - 1944. [Full Text] [PDF]

				M. L. C. Khoo, N. J. P. Beasley, S. Ezzat, J. L. Freeman, and S. L. Asa Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1814 - 1818. [Abstract] [Full Text] [PDF]

				G. Belchetz, C. C. Cheung, J. Freeman, I. B. Rosen, I. J. Witterick, and S. L. Asa Hurthle Cell Tumors: Using Molecular Techniques to Define a Novel Classification System Arch Otolaryngol Head Neck Surg, March 1, 2002; 128(3): 237 - 240. [Abstract] [Full Text] [PDF]

				G. Chiappetta, P. Toti, F. Cetta, A. Giuliano, F. Pentimalli, I. Amendola, S. Lazzi, M. Monaco, L. Mazzuchelli, P. Tosi, et al. The RET/PTC Oncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell Adenomas and Carcinomas), but Not in Oncocytic Hyperplastic Lesions J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 364 - 369. [Abstract] [Full Text] [PDF]

				F. Basolo, R. Giannini, C. Monaco, R. M. Melillo, F. Carlomagno, M. Pancrazi, G. Salvatore, G. Chiappetta, F. Pacini, R. Elisei, et al. Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma Am. J. Pathol., January 1, 2002; 160(1): 247 - 254. [Abstract] [Full Text] [PDF]

				C. C. Cheung, B. Carydis, S. Ezzat, Y. C. Bedard, and S. L. Asa Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2187 - 2190. [Abstract] [Full Text]